Genetically engineered mice that more accurately reproduce the conditions of Alzheimer's disease

June 6, 2014, RIKEN
Figure 1: Amyloid beta peptide (brown) accumulation in the brain of the new double-mutant mouse model of Alzheimer’s disease. Credit: Takaomi Saido, RIKEN Brain Science Institute

Potential therapies for Alzheimer's disease are currently studied using genetically engineered mouse strains that display many of the key features of the disease. Most of these mouse models overexpress the amyloid precursor protein (APP)—a large protein that when cut by enzymes releases amyloid beta (Aβ), the peptide responsible for the formation of pathogenic plaques in the brains of Alzheimer's patients. The problem with this approach, however, is that APP can also give rise to other peptide fragments that are either toxic or neuroprotective, making it difficult to translate research findings to the human disease.

Takaomi Saido, Takashi Saito and colleagues from the Laboratory for Proteolytic Neuroscience at the RIKEN Brain Science Institute have now developed a pair of mouse models that overproduce Aβ without overexpressing APP. "Our mice could be useful tools to evaluate drug targets and to elucidate the pathogenic molecular mechanisms of Alzheimer's disease," says Saido.

To 'build' their first mouse model, Saido's team manipulated the mouse gene that encodes APP using a genetic engineering technique known as a 'knock-in' strategy. The researchers first made the Aβ-coding portion of the APP gene more human-like. They then 'knocked in' two specific mutations found in people with family histories of early-onset Alzheimer's disease. One of these, the so-called Swedish mutation, increases the total amount of Aβ; the other, the Iberian mutation, adjusts the ratio of Aβ forms, tipping the balance toward a type that is the most likely to cause plaque build-up. Neither mutation affects the overall expression of APP.

These mice began to accumulate Aβ beginning at around six months of age (Fig. 1). They subsequently developed several Alzheimer's-related symptoms, including amyloid plaques in the brain's cortex and hippocampus, with signs of neuroinflammation and synaptic loss in the vicinity of the plaques. The mice also showed signs of cognitive and memory impairment at 18 months of age.

In parallel, the researchers created another that expressed the Arctic mutation in addition to the Swedish and Iberian ones. The symptoms in these mice were generally more severe and rapid. "The triple-mutant strain would be a useful tool to elucidate pathogenic molecular mechanisms after Aβ deposition," notes Saido, "while the double-mutant strain could help search for ways to prevent the disease."

The new mouse models provide a means of studying the effects of Aβ in the brain without the complicating effects of overexpressed APP, and are expected to allow researchers to more accurately evaluate novel therapies for Alzheimer's.

Explore further: The benefits of a spotless mind

More information: Saito, T., Matsuba, Y., Mihira, N., Takano, J., Nilsson, P., Itohara, S., Iwata, N. & Saido, T. C. "Single App knock-in mouse models of Alzheimer's disease." Nature Neuroscience 17, 661–663 (2014). DOI: 10.1038/nn.3697

Related Stories

The benefits of a spotless mind

November 15, 2013
Alzheimer's disease is an age-related memory disorder characterized by the accumulation of clumps of the toxic amyloid-β (Aβ) protein fragment in the extracellular space around neurons in the brain. Drugs that help to 'clean ...

New mouse model could revolutionize research in Alzheimer's disease

April 13, 2014
In a study published today in Nature Neuroscience, a group of researchers led by Takaomi Saido of the RIKEN Brain Science Institute in Japan have reported the creation of two new mouse models of Alzheimer's disease that may ...

New therapeutic target discovered for Alzheimer's disease

March 18, 2014
A team of scientists from the University of California, San Diego School of Medicine, the Medical University of South Carolina and San Diego-based American Life Science Pharmaceuticals, Inc., report that cathepsin B gene ...

Characterizing a toxic offender

December 9, 2011
The brains of individuals with Alzheimer's disease contain protein aggregates called plaques and tangles, which interfere with normal communication between nerve cells and cause progressive learning and memory deficits. Now, ...

Compound reverses symptoms of Alzheimer's disease in mice, research shows

May 20, 2014
A molecular compound developed by Saint Louis University scientists restored learning, memory and appropriate behavior in a mouse model of Alzheimer's disease, according to findings in the May issue of the Journal of Alzheimer's ...

Understanding the molecular mechanisms underlying Alzheimer's disease

June 10, 2013
The accumulation of amyloid-β (Aβ) in the brains of Alzheimer's disease (AD) patients is known to be associated with memory loss and neuronal degeneration, but the mechanism of Aβ pathogenesis is not fully understood.

Recommended for you

Alzheimer's disease: Neuronal loss very limited

January 17, 2018
Frequently encountered in the elderly, Alzheimer's is considered a neurodegenerative disease, which means that it is accompanied by a significant, progressive loss of neurons and their nerve endings, or synapses. A joint ...

Anxiety: An early indicator of Alzheimer's disease?

January 12, 2018
A new study suggests an association between elevated amyloid beta levels and the worsening of anxiety symptoms. The findings support the hypothesis that neuropsychiatric symptoms could represent the early manifestation of ...

One of the most promising drugs for Alzheimer's disease fails in clinical trials

January 11, 2018
To the roughly 400 clinical trials that have tested some experimental treatment for Alzheimer's disease and come up short, we can now add three more.

Different disease types associated with distinct amyloid-beta prion strains found in Alzheimer's patients

January 9, 2018
An international team of researchers has found different disease type associations with distinct amyloid-beta prion strains in the brains of dead Alzheimer's patients. In their paper published in Proceedings of the National ...

Advances in brain imaging settle debate over spread of key protein in Alzheimer's

January 5, 2018
Recent advances in brain imaging have enabled scientists to show for the first time that a key protein which causes nerve cell death spreads throughout the brain in Alzheimer's disease - and hence that blocking its spread ...

Molecular mechanism behind HIV-associated dementia revealed

January 5, 2018
For the first time, scientists have identified and inhibited a molecular process that can lead to neurodegeneration in patients with HIV, according to a Northwestern Medicine study published in Nature Communications.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.